RSV Vaccine Eligibility Expands - Takeaways - MDSpire

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 3 min

Share

  • 1

    The FDA has expanded the RSV vaccine Arexvy's approval to include adults aged 18 to 49 at increased risk for severe disease.

  • 2

    Previously, Arexvy was approved for adults aged 60 and older and those aged 50 to 59 with increased risk.

  • 3

    An estimated 21 million adults under 50 in the US have risk factors for severe RSV infection.

  • 4

    A phase 3b trial showed noninferior immune response and consistent safety profile for the vaccine in the younger high-risk group.

  • 5

    Common adverse events after vaccination included injection site pain, fatigue, and headache, generally mild to moderate.

Original Source(s)

RSV Vaccine Eligibility Expands

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Commentary: The effects of postponing BCG vaccination on the risk of BCG-related complications among patients with severe combined immunodeficiency disease in Saudi Arabia

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Human Papillomavirus Vaccine Discourse and Sentiment on Reddit Before and After COVID-19: Mixed Methods Retrospective Cross-Sectional Study